In patients with high-risk tumors, those treated with segmental ureterectomy did not have worse overall survival compared with those who underwent radical nephroureterectomy.
As current guidelines only include a weak recommendation to offer perioperative chemotherapy to patients with muscle-invasive upper tract urothelial carcinoma, a new meta-analysis including evidence up to February 2020 provides potentially useful information.
Survival was significantly improved in patients with greater disease burden.
The 2020 update highlights the importance of accurate diagnosis of upper tract urothelial carcinoma, risk stratification, close follow-up of patients receiving kidney-sparing management, and other key aspects of care.
Patients who underwent ureteroscopic management of low-risk UTUC had a 5-year cancer-specific survival rate of 92.6%.
Overall and disease-free survival among patients undergoing surgical resection for MIUC is low despite increasing use of neoadjuvant chemotherapy.
In a study, modified Glasgow prognostic score predicted nonorgan-confined disease and lymph node invasion at surgery.
The grade-to-grade match between URS biopsy and final pathology was 66% for low-grade and 97% for high-grade tumors , according to a recent systematic review and meta-analysis.
In a large case series, stage IV disease at diagnosis and 3 or more metastatic sites were both associated with worse prognosis.
A study of 13,438 patients with upper tract urothelial carcinoma in The Netherlands found that the incidence of the cancer increased significantly from 1993 to 2017, with no improvement in survival except for those with metastatic disease.